Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
![]() |
![]() ![]() |
Ultima descărcare din IBN: 2024-06-02 22:45 |
![]() BAZINET, Michel, ANDERSON, Mark, PÂNTEA, Victor, PLĂCINTĂ, Gheorghe, MOSCALU, Iurie, CEBOTARESCU, Valentin, COJUHARI, Lilia, JIMBEI, Pavlina, IAROVOI, Liviu, SMESHNOI, Valentina, MUSTEAŢĂ, Tatiana, JUCOV, Alina, GERSCH, Jeffrey, HOLZMAYER, Vera, KUHNS, Mary C., CLOHERTY, Gavin A., VAILLANT, Andrew. Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and REP 401 studies. In: Journal of Hepatology, 2020, vol. 73, supl. nr. 1, p. 142. ISSN 0168-8278. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Journal of Hepatology | |
Volumul 73, Supliment nr. 1 / 2020 / ISSN 0168-8278 /ISSNe 1600-0641 | |
|
|
Pag. 142-142 | |
![]() |
|
Rezumat | |
Background and aims: After completion of NAP-based combination therapy with pegIFN and follow-up in the REP 301-LTF study (3.5 years) and REP 401 study (48 weeks), combined HBV outcomes were functional cure (HBsAg <0.05 IU/mL, HBV DNA target not detected, normal ALT [FC]) in 18/52 (35%), virologic control (HBV DNA ≤2000 IU/mL, normal ALT [VC]) in 19/52 (36%) and rebound (R) in 15/52 (29%) of participants. The goal of this study was to analyze the relationship between HBV outcome and experimental virologic markers of HBV infection. Methods: Frozen serum samples (n = 1153) from all 52 participants in the REP 301/REP 301-LTF and REP 401 studies were analyzed by the following: 1. Abbott ARCHITECT HBsAg NEXT (analytical sensitivity 0.005 IU/ mL). 2. Abbott research use only (RUO) assays for HBsAg isoforms (large, medium, small). 3. Abbott RUO assay for HBsAg/anti-HBs immune complexes (HBsAg IC). 4. Abbott RUO assay for pregenomic HBV RNA (pgRNA). 5. Fujirebio HBcrAg (LLOQ 3log10 U/mL). Results: All participants experiencing HBsAg loss (<0.05 IU/mL) during therapy (28/52) rapidly became negative with HBsAg Next. HBsAg <0.005 IU/mL was confirmed at the end of follow-up in 18/18 functional cure and 1/1 virologic control participants with previous HBsAg <0.05 IU/mL. A more rapid reduction of S-HBsAg relative to the reduction of other HBsAg isoforms occurred in 39/40 participants with HBsAg decline >2 log10 from baseline, consistent with targeting SVPs. At the end of follow-up, HBsAg isoforms were detectable in 0/18 (FC), 17/19 (VC) and 15/15 (R) participants. HBsAg IC (relative luminescence units or RLU) were in the positive range in 30/52 participants at baseline and at the end of follow-up in 0/18 (FC), 5/19 (VC) and 10/15 (R) participants. At baseline, HBV RNA and HBcrAg were present in 42 and 34 participants. HBV RNA loss on therapy occurred in 5/ 14 (FC), 5/16 (VC) and 1/12 (R) participants. HBcrAg < LLOQ on therapy occurred in 5/9 (FC), 7/15 (VC) and 3/10 (R) participants. At the end of follow-up, both HBV RNA and HBcrAg were > LLOQ in 1/18 (FC), 15/19 (VC) and 13/15 (R) participants. Conclusion: Functional cure of HBV infection following NAP-based combination therapy is profound, with HBsAg <0.005 IU/mL and both HBV RNA and HBcrAg < LLOQ. NEXT negativity and the absence of HBsAg IC RLUs in the positive range at the end of follow-up in FC participants suggests efficient reduction in integrated HBV DNA. |
|
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-201380</cfResPublId> <cfResPublDate>2020-04-01</cfResPublDate> <cfStartPage>142</cfStartPage> <cfISSN>0168-8278</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/201380</cfURI> <cfTitle cfLangCode='EN' cfTrans='o'>Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and REP 401 studies</cfTitle> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Background and aims: After completion of NAP-based combination therapy with pegIFN and follow-up in the REP 301-LTF study (3.5 years) and REP 401 study (48 weeks), combined HBV outcomes were functional cure (HBsAg <0.05 IU/mL, HBV DNA target not detected, normal ALT [FC]) in 18/52 (35%), virologic control (HBV DNA ≤2000 IU/mL, normal ALT [VC]) in 19/52 (36%) and rebound (R) in 15/52 (29%) of participants. The goal of this study was to analyze the relationship between HBV outcome and experimental virologic markers of HBV infection. Methods: Frozen serum samples (n = 1153) from all 52 participants in the REP 301/REP 301-LTF and REP 401 studies were analyzed by the following: 1. Abbott ARCHITECT HBsAg NEXT (analytical sensitivity 0.005 IU/ mL). 2. Abbott research use only (RUO) assays for HBsAg isoforms (large, medium, small). 3. Abbott RUO assay for HBsAg/anti-HBs immune complexes (HBsAg IC). 4. Abbott RUO assay for pregenomic HBV RNA (pgRNA). 5. Fujirebio HBcrAg (LLOQ 3log10 U/mL). Results: All participants experiencing HBsAg loss (<0.05 IU/mL) during therapy (28/52) rapidly became negative with HBsAg Next. HBsAg <0.005 IU/mL was confirmed at the end of follow-up in 18/18 functional cure and 1/1 virologic control participants with previous HBsAg <0.05 IU/mL. A more rapid reduction of S-HBsAg relative to the reduction of other HBsAg isoforms occurred in 39/40 participants with HBsAg decline >2 log10 from baseline, consistent with targeting SVPs. At the end of follow-up, HBsAg isoforms were detectable in 0/18 (FC), 17/19 (VC) and 15/15 (R) participants. HBsAg IC (relative luminescence units or RLU) were in the positive range in 30/52 participants at baseline and at the end of follow-up in 0/18 (FC), 5/19 (VC) and 10/15 (R) participants. At baseline, HBV RNA and HBcrAg were present in 42 and 34 participants. HBV RNA loss on therapy occurred in 5/ 14 (FC), 5/16 (VC) and 1/12 (R) participants. HBcrAg < LLOQ on therapy occurred in 5/9 (FC), 7/15 (VC) and 3/10 (R) participants. At the end of follow-up, both HBV RNA and HBcrAg were > LLOQ in 1/18 (FC), 15/19 (VC) and 13/15 (R) participants. Conclusion: Functional cure of HBV infection following NAP-based combination therapy is profound, with HBsAg <0.005 IU/mL and both HBV RNA and HBcrAg < LLOQ. NEXT negativity and the absence of HBsAg IC RLUs in the positive range at the end of follow-up in FC participants suggests efficient reduction in integrated HBV DNA.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-55509</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-91728</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11460</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11476</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11418</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-10924</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-10995</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-29209</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11184</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-13477</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-29207</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-48534</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-91744</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-91746</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-91748</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-91749</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-55510</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-55509</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-55509-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Bazinet</cfFamilyNames> <cfFirstNames>Michel</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-91728</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-91728-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Anderson</cfFamilyNames> <cfFirstNames>Mark</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11460</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11460-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Pântea</cfFamilyNames> <cfFirstNames>Victor</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11476</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11476-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Plăcintă</cfFamilyNames> <cfFirstNames>Gheorghe</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11418</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11418-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Москалу</cfFamilyNames> <cfFirstNames>Юрие</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-10924</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10924-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Cebotarescu</cfFamilyNames> <cfFirstNames>Valentin</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-10995</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10995-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Cojuhari</cfFamilyNames> <cfFirstNames>Lilia</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-29209</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-29209-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Jimbei</cfFamilyNames> <cfFirstNames>Pavlina</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11184</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11184-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Iarovoi</cfFamilyNames> <cfFirstNames>Liviu</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-13477</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-13477-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Smeshnoi</cfFamilyNames> <cfFirstNames>Valentina</cfFirstNames> <cfFamilyNames>Смешной</cfFamilyNames> <cfFirstNames>Валентина</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-29207</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-29207-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Musteaţă</cfFamilyNames> <cfFirstNames>Tatiana</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-48534</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-48534-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Jucov</cfFamilyNames> <cfFirstNames>Alina</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-91744</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-91744-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Gersch</cfFamilyNames> <cfFirstNames>Jeffrey</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-91746</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-91746-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Holzmayer</cfFamilyNames> <cfFirstNames>Vera</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-91748</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-91748-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Kuhns</cfFamilyNames> <cfFirstNames>Mary C.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-91749</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-91749-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Cloherty</cfFamilyNames> <cfFirstNames>Gavin A.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-55510</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-55510-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2020-04-01T24:00:00</cfStartDate> <cfFamilyNames>Vaillant</cfFamilyNames> <cfFirstNames>Andrew</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>